SLAWOMIR PUSZKARSKI: Open Payments
NPI 1679606560 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$305 in 13 payments from 7 companies in 2025. Trend: 2023 $302 · 2024 $93 · 2025 $305
Food & beverage: $305
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $71 |
| E.R. Squibb & Sons, L.L.C. | 2 | $71 |
| ABBVIE INC. | 2 | $50 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Alkermes, Inc. | 2 | $37 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
Products named: CAPLYTA, COBENFY, VRAYLAR, Auvelity, ARISTADA, SHINGRIX, REXULTI.
Industry payments across IL — which companies pay providers there.
